Stock listing
Helsinki:OPTOMED Optomed Oyj Osake
Home listing (Helsinki) of Optomed Oyj
Follow Optomed Oyj into a list and get an email when it puts out news.
Share price · OMXHEX:OPTOMED
€1.58 EUR -0.12 (-7.1%)
Close on Nov 20, 2026
- Day range
- €1.51 – €1.63 EURNov 20, 2026
- Volume
- 71,989 sharesNov 20, 2026
- Market cap
- €33.93M EURAt the close on Nov 20, 2026 · price × 21.47M shares outstanding
- 52-week range
- €1.32 – €4.10 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €72,985 EURMedian day 31,636 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Helsinki:OPTOMED · Home | €1.58 EUR | -0.12 (-7.1%) | 71,989 | €1.632 | €1.632 | €1.506 | €1.70 | Close on Nov 20, 2026 |
| Frankfurt:36U0 | €1.554 EUR | -0.116 (-6.9%) | — | €1.554 | €1.554 | €1.554 | €1.67 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXHEX:OPTOMED · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.58 | -0.12 | -7.1% | €1.632 | €1.632 | €1.506 | 71,989 | |
| €1.70 | -0.056 | -3.2% | €1.772 | €1.79 | €1.67 | 46,458 | |
| €1.756 | -0.08 | -4.4% | €1.864 | €1.90 | €1.756 | 116,308 | |
| €1.836 | +0.176 | +10.6% | €1.702 | €1.85 | €1.688 | 179,600 | |
| €1.66 | -0.004 | -0.2% | €1.662 | €1.71 | €1.654 | 37,493 | |
| €1.664 | +0.004 | +0.2% | €1.658 | €1.664 | €1.62 | 41,847 | |
| €1.66 | -0.066 | -3.8% | €1.694 | €1.694 | €1.64 | 40,872 | |
| €1.726 | +0.214 | +14.2% | €1.762 | €1.82 | €1.622 | 385,323 | |
| €1.512 | +0.002 | +0.1% | €1.51 | €1.588 | €1.50 | 80,258 | |
| €1.51 | -0.016 | -1.0% | €1.526 | €1.53 | €1.486 | 42,016 | |
| €1.526 | +0.054 | +3.7% | €1.472 | €1.534 | €1.468 | 56,762 | |
| €1.472 | +0.062 | +4.4% | €1.41 | €1.504 | €1.41 | 65,102 | |
| €1.41 | +0.042 | +3.1% | €1.368 | €1.41 | €1.322 | 31,659 | |
| €1.368 | +0.016 | +1.2% | €1.352 | €1.368 | €1.33 | 13,631 | |
| €1.352 | -0.022 | -1.6% | €1.372 | €1.374 | €1.338 | 52,712 | |
| €1.374 | -0.008 | -0.6% | €1.396 | €1.398 | €1.37 | 15,442 | |
| €1.382 | -0.038 | -2.7% | €1.43 | €1.43 | €1.372 | 7,705 | |
| €1.42 | +0.032 | +2.3% | €1.45 | €1.45 | €1.37 | 12,282 | |
| €1.388 | -0.018 | -1.3% | €1.412 | €1.436 | €1.388 | 17,986 | |
| €1.406 | +0.046 | +3.4% | €1.352 | €1.412 | €1.352 | 28,039 | |
| €1.36 | 0.00 | 0.0% | €1.36 | €1.386 | €1.352 | 17,220 | |
| €1.36 | -0.046 | -3.3% | €1.406 | €1.406 | €1.344 | 31,628 | |
| €1.406 | +0.008 | +0.6% | €1.40 | €1.424 | €1.38 | 14,074 | |
| €1.398 | +0.006 | +0.4% | €1.392 | €1.45 | €1.378 | 16,451 | |
| €1.392 | -0.018 | -1.3% | €1.396 | €1.40 | €1.382 | 6,523 | |
| €1.41 | +0.038 | +2.8% | €1.372 | €1.44 | €1.372 | 25,294 | |
| €1.372 | -0.058 | -4.1% | €1.43 | €1.43 | €1.36 | 57,342 | |
| €1.43 | -0.026 | -1.8% | €1.462 | €1.462 | €1.402 | 23,579 | |
| €1.456 | +0.024 | +1.7% | €1.43 | €1.488 | €1.40 | 33,003 | |
| €1.432 | +0.046 | +3.3% | €1.392 | €1.434 | €1.38 | 41,028 | |
| €1.386 | -0.02 | -1.4% | €1.39 | €1.422 | €1.382 | 67,423 | |
| €1.406 | -0.054 | -3.7% | €1.46 | €1.46 | €1.38 | 67,455 | |
| €1.46 | -0.01 | -0.7% | €1.472 | €1.472 | €1.396 | 129,863 | |
| €1.47 | -0.04 | -2.6% | €1.51 | €1.56 | €1.47 | 22,257 | |
| €1.51 | -0.016 | -1.0% | €1.526 | €1.53 | €1.50 | 20,673 | |
| €1.526 | -0.02 | -1.3% | €1.55 | €1.55 | €1.516 | 18,315 | |
| €1.546 | -0.004 | -0.3% | €1.548 | €1.552 | €1.524 | 18,555 | |
| €1.55 | +0.026 | +1.7% | €1.524 | €1.558 | €1.504 | 19,908 | |
| €1.524 | -0.03 | -1.9% | €1.562 | €1.562 | €1.51 | 8,908 | |
| €1.554 | +0.03 | +2.0% | €1.52 | €1.562 | €1.492 | 19,502 | |
| €1.524 | -0.022 | -1.4% | €1.534 | €1.552 | €1.48 | 117,980 | |
| €1.546 | +0.006 | +0.4% | €1.54 | €1.57 | €1.522 | 63,259 | |
| €1.54 | -0.02 | -1.3% | €1.552 | €1.552 | €1.504 | 69,289 | |
| €1.56 | -0.004 | -0.3% | €1.566 | €1.598 | €1.552 | 51,198 | |
| €1.564 | -0.016 | -1.0% | €1.58 | €1.58 | €1.56 | 8,462 | |
| €1.58 | -0.002 | -0.1% | €1.554 | €1.596 | €1.534 | 31,843 | |
| €1.582 | +0.012 | +0.8% | €1.56 | €1.598 | €1.55 | 27,404 | |
| €1.57 | -0.024 | -1.5% | €1.594 | €1.598 | €1.564 | 26,020 | |
| €1.594 | -0.016 | -1.0% | €1.61 | €1.61 | €1.57 | 24,001 | |
| €1.61 | -0.01 | -0.6% | €1.622 | €1.622 | €1.562 | 50,672 | |
| €1.62 | -0.02 | -1.2% | €1.64 | €1.652 | €1.614 | 27,563 | |
| €1.64 | 0.00 | 0.0% | €1.662 | €1.68 | €1.62 | 64,777 | |
| €1.64 | +0.022 | +1.4% | €1.62 | €1.648 | €1.602 | 84,360 | |
| €1.618 | +0.018 | +1.1% | €1.60 | €1.664 | €1.578 | 31,644 | |
| €1.60 | -0.02 | -1.2% | €1.64 | €1.642 | €1.59 | 40,319 | |
| €1.62 | -0.038 | -2.3% | €1.678 | €1.68 | €1.62 | 39,256 | |
| €1.658 | -0.042 | -2.5% | €1.69 | €1.69 | €1.652 | 15,628 | |
| €1.70 | +0.038 | +2.3% | €1.67 | €1.702 | €1.638 | 26,468 | |
| €1.662 | -0.016 | -1.0% | €1.70 | €1.70 | €1.658 | 10,888 | |
| €1.678 | -0.028 | -1.6% | €1.706 | €1.716 | €1.678 | 32,911 | |
| €1.706 | +0.022 | +1.3% | €1.708 | €1.72 | €1.68 | 27,775 | |
| €1.684 | -0.012 | -0.7% | €1.698 | €1.724 | €1.658 | 23,259 | |
| €1.696 | +0.034 | +2.0% | €1.646 | €1.702 | €1.63 | 28,988 | |
| €1.662 | -0.016 | -1.0% | €1.68 | €1.68 | €1.646 | 22,531 |
- Ticker
- Helsinki:OPTOMED
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Helsinki
- Currency
- EUR
What changed lately
Latest news release · Sep 25, 2026
Optomed's Board of Directors has resolved to establish a new stock option plan
Latest deck · Nov 6, 2026
Q3 2026 Earnings Presentation
Earnings · 16 slides
Latest news
Optomed's Board of Directors has resolved to establish a new stock option plan
Sep 25, 2026
Closed €1.55 (+1.7%) on Sep 25, 2026
Optomed Oyj receives EcoVadis Committed Badge for sustainability
Sep 21, 2026
Closed €1.55 (+0.4%) on Sep 21, 2026
Directed share issue without payment to implement Board remuneration
Aug 14, 2026
Closed €1.64 (-3.5%) on Aug 14, 2026
Optomed: January-June 2026 half-year report will be published on 14 Aug 2026
Aug 7, 2026
Closed €1.65 (+3.1%) on Aug 7, 2026
Optomed: January-June 2026 half-year report will be published on 14 August 2026
Aug 7, 2026
Closed €1.65 (+3.1%) on Aug 7, 2026
Inside Information: Optomed receives a large order in the US
Jun 18, 2026
Closed €1.66 (-0.5%) on Jun 22, 2026
Decisions of the Organization Meeting of Optomed's Board of Directors
May 8, 2026
Closed €1.53 (-0.6%) on May 11, 2026
Decisions of the Annual General Meeting
May 8, 2026
Closed €1.54 (-1.4%) on May 8, 2026
Interim Report, January – March 2026
May 6, 2026
Closed €1.63 (-30.6%) on May 6, 2026
Interim Report, January – March 2026, presentation
May 6, 2026
Closed €1.63 (-30.6%) on May 6, 2026
Optomed Oyj on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 12 in the last 12 months · 12 in all · newest Sep 25, 2026 · oldest 2025
- Decks
- 35 decks · latest Nov 6, 2026
Where Optomed Oyj is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Helsinki:OPTOMED · Home listing · This page | Helsinki | Finland | EUR |
| LS Exchange:A2PWGR | LS Exchange | Germany | EUR |
| Aquis:OPTOMH | Aquis | United Kingdom | EUR |
| Aquis:OPTOMH | Aquis | United Kingdom | EUR |
| Dusseldorf:36U0 | Dusseldorf | Germany | EUR |
| Frankfurt:36U0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2PWGR | Lang & Schwarz | Germany | EUR |
Valuation
EV/sales 1.8× against a median of 1.3×: 7th lowest of 9 Medical devices & supplies companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €29.59M EUR
- P/E
- Loss
- EV/sales
- 1.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.6×
- Gross margin
- 5.4%
- Operating margin
- −35.2%
- Net margin
- −33.9%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Optomed Oyj Class A · OMXHEX:OPTOMED | US$37.24M | US$32.48M | n/a | 1.8× | n/a | 1.6× | −33.9% | 0.1× | n/a |
| electroCore, Inc. · NASDAQ:ECOR | US$40.78M | US$41.51M | n/a | 1.1× | n/a | n/a | −33.5% | n/a | 1.91 |
| Elutia, Inc. · NASDAQ:ELUT | US$39.86M | US$18.87M | 0.7× | 1.5× | n/a | 2.6× | 441.2% | 0.5× | -0.06 |
| DRGEM Corp. · KRX:263690 | US$38.81M | US$32.33M | 4.3× | 0.4× | 3.2× | 0.5× | 11.2% | 0.1× | n/a |
| Cryofocus Medtech (Shanghai) Co. Ltd. Class H · HKEX:6922 | US$37.93M | US$29.03M | n/a | 2.0× | n/a | 3.8× | −40.1% | 0.0× | n/a |
| Ocumetics Technology Corp · TSXV:OTC | US$37.38M | US$37.60M | n/a | n/a | n/a | n/a | n/a | n/a | 0.14 |
| Sensus Healthcare, Inc. · NASDAQ:SRTS | US$37.20M | US$24.56M | n/a | 1.5× | n/a | 1.1× | −96.5% | 0.0× | 1.08 |
| Epiminder Ltd. · ASX:EPI | US$36.57M | −US$13.60M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | n/a |
| Avita Corporation · TPEX:4735 | US$35.63M | US$14.80M | 5.1× | 0.5× | 4.4× | 1.0× | 23.8% | 0.0× | n/a |
| SELVAS Healthcare, Inc. · KRX:208370 | US$35.56M | US$15.07M | 5.5× | 0.6× | 8.0× | 0.6× | 27.5% | 0.0× | n/a |
| Taiwan Biomaterial Co., Ltd. · TPEX:6649 | US$35.55M | US$28.06M | 35.3× | 5.1× | 26.5× | 1.8× | 18.2% | 0.0× | n/a |
| Median of the others | US$37.29M | US$26.31M | 5.1× | 1.3× | 6.2× | 1.1× | 14.7% | 0.0× | 0.61 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.27 EUR · Analysts' mean
- EPS, year to Dec 2026
- -0.13 · 2 analysts
- Revenue, year to Dec 2026
- 17.5M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Juho Himberg | CEO |
| Sakari Knuutti | Chief Financial Officer |
| Laura Piila | Vice President, Devices |
| Markku Myllylä | Vice President, Software |
Board
| Director | Role |
|---|---|
| Catherine Calarco | Member of the Board of Directors |
| Kristiina Leppänen | Member of the Board of Directors |
| Leana Wen | Member of the Board of Directors |
| Petri Salonen | Director |
| Reijo Tauriainen | Member of the Board of Directors |
| Sameer Badlani | Member of the Board of Directors |
| Seppo Mäkinen | Member of the Board of Directors |
| Ty Lee | Member of the Board of Directors |
Events
- Next results
- Feb 18, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 6, 2026 · Before open | +14.2% |
| Q2 2026 | Aug 14, 2026 · Before open | −3.5% |
| Q1 2026 | May 6, 2026 · Before open | −30.6% |
| Q4 2025 | Feb 10, 2026 · Before open | −25.5% |
| Q3 2025 | Nov 6, 2025 · Before open | +2.6% |
| Q2 2025 | Aug 7, 2025 · Before open | −11.0% |
| Q1 2025 | May 6, 2025 · Before open | +8.5% |
| Q4 2024 | Feb 13, 2025 · Before open | +7.6% |
| Q3 2024 | Nov 7, 2024 · Before open | +17.6% |
| Q2 2024 | Aug 8, 2024 · Before open | −11.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | +3.9% |
| Q4 2023 | Feb 15, 2024 · Before open | −4.9% |
| Q3 2023 | Nov 3, 2023 · Before open | +5.2% |
| Q2 2023 | Aug 4, 2023 · Before open | −6.0% |
| Q1 2023 | May 5, 2023 · Before open | −1.2% |
| Q4 2022 | Feb 17, 2023 · Before open | −5.3% |
| Q3 2022 | Nov 3, 2022 · Before open | +21.3% |
| Q2 2022 | Aug 4, 2022 · Before open | +3.9% |
| Q1 2022 | May 5, 2022 · Before open | −4.6% |
| Q4 2021 | Feb 17, 2022 · Before open | −11.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 16 slides | Nov 6, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 16 slides | Aug 14, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 16 slides | Feb 10, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 16 slides | Nov 6, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 16 slides | Aug 7, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 11 slides | May 6, 2025 |
| Investor Presentation (March 2025) | Investor deck | 12 slides | March 2025 |
| Q4 2024 Earnings Presentation | Earnings | 15 slides | Feb 13, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 15 slides | Nov 7, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 15 slides | Aug 8, 2024 |
All 35 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new shares (directed share issue) Closed: €6M raised · €3.4 a share · UB Asset Management Ltd +1 Dealers: UB Asset Management Ltd (lead), UB Clairfield Corporate Finance Ltd Use of proceeds: Ramp up production, start regulatory clearance processes (incl. clinical trials for Lumo AI in the US), improve sales and expand AI services globally | Dec 10, 2025 | US$6.99M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.1M | 15.0M | 15.1M | 14.7M | 14.8M | 13.0M | 15.0M | 14.5M | 6.90M | 6.61M |
| Cost of revenue | 17.5M | 5.37M | 4.86M | 5.45M | 5.10M | 4.21M | 5.29M | 4.95M | 3.12M | 2.99M |
| Gross profit | -370.0K | 9.67M | 10.2M | 9.21M | 9.75M | 8.80M | 9.69M | 9.51M | 3.78M | 3.62M |
| Research and development | 1.64M | 297.0K | 2.95M | 361.0K | 412.0K | 276.0K | 356.0K | 1.07M | 227.0K | 532.0K |
| Selling, general and administrative | 1.63M | 3.20M | 2.51M | 765.0K | 866.0K | 714.0K | 504.0K | 1.65M | 220.0K | 251.0K |
| Operating income | -6.05M | -5.96M | -3.97M | -4.67M | -4.37M | -2.75M | -2.21M | -665.0K | -2.83M | -2.61M |
| Depreciation and amortization | 2.52M | 2.50M | 2.19M | 3.15M | 2.69M | 2.17M | 2.26M | 1.81M | 1.04M | 746.0K |
| EBITDA | -3.53M | -3.46M | -1.78M | -1.53M | -1.68M | -572.0K | 51.0K | 1.15M | -1.78M | -1.86M |
| Interest expense | 1.26M | 776.0K | 288.0K | 268.0K | 165.0K | 171.0K | 365.0K | 594.0K | 197.0K | 89.0K |
| Income before tax | -6.72M | -5.52M | -4.52M | -5.55M | -4.33M | -3.25M | -2.95M | -1.22M | -2.89M | -2.76M |
| Income tax | -77.0K | -66.0K | -78.0K | -79.0K | -78.0K | -70.0K | -77.0K | 48.0K | -3.00K | -3.00K |
| Net income | -6.64M | -5.45M | -4.44M | -5.47M | -4.25M | -3.18M | -2.88M | -1.27M | -2.89M | -2.76M |
| Earnings per share, basic | -0.34 | -0.29 | -0.27 | -0.37 | -0.32 | -0.24 | -0.32 | -0.10 | -0.22 | -0.21 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 9.91M | 10.5M | 7.12M | 8.52M | 6.80M | 10.6M | 18.9M | 2.00M | 1.03M | 1.62M |
| Receivables | 3.47M | 3.27M | 3.19M | 4.57M | 4.63M | 3.64M | 4.13M | 3.40M | 962.0K | 1.02M |
| Inventory | 2.38M | 1.96M | 2.82M | 3.00M | 2.94M | 2.54M | 2.47M | 1.12M | 1.06M | 1.58M |
| Current assets | 15.8M | 15.7M | 13.1M | 16.1M | 14.4M | 16.8M | 25.5M | 6.52M | 3.71M | 4.95M |
| Property, plant and equipment | 2.11M | 2.11M | 2.18M | 2.30M | 1.64M | 1.52M | 1.48M | 1.82M | ||
| Goodwill | 4.26M | 4.26M | 4.26M | 4.26M | 4.26M | 4.26M | 4.26M | 4.26M | ||
| Total assets | 32.0M | 31.8M | 29.1M | 31.3M | 29.0M | 31.1M | 39.6M | 21.1M | 9.92M | 10.0M |
| Accounts payable | 1.16M | 891.0K | 782.0K | 869.0K | 944.0K | 595.0K | 1.67M | 732.0K | 522.0K | 668.0K |
| Current liabilities | 6.59M | 5.58M | 5.05M | 5.23M | 4.91M | 3.49M | 7.56M | 10.5M | 2.70M | 2.90M |
| Long-term debt | 371.0K | 1.31M | 2.36M | 4.29M | 5.75M | 6.19M | 8.10M | 2.99M | 4.96M | |
| Total debt | 2.71M | 3.81M | 4.86M | 6.74M | 8.23M | 7.72M | 11.0M | 11.3M | 6.15M | 3.79M |
| Total liabilities | 7.96M | 8.14M | 8.72M | 11.0M | 11.9M | 11.0M | 17.0M | 15.6M | 8.76M | 6.50M |
| Shareholders' equity | 24.0M | 23.6M | 20.4M | 20.3M | 17.1M | 20.1M | 22.6M | 5.55M | 1.16M | 3.52M |
| Shares outstanding | 19.8M | 18.7M | 16.7M | 14.6M | 13.4M | 13.3M | 8.94M | 13.2M | 13.2M | 13.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2.48M | -1.60M | -615.0K | -2.37M | -2.94M | -2.80M | 161.0K | -76.0K | -766.0K | -810.0K |
| Capital spending | -2.36M | -2.12M | -2.41M | -3.03M | -2.57M | -1.82M | -1.44M | -1.70M | -1.93M | -1.91M |
| Free cash flow | -4.84M | -3.71M | -3.03M | -5.40M | -5.51M | -4.62M | -1.27M | -1.77M | -2.69M | -2.72M |
| Cash from investing | -2.36M | -2.12M | -2.41M | -3.03M | -2.57M | -1.82M | -1.43M | -8.77M | -1.91M | -1.89M |
| Cash from financing | 4.19M | 7.08M | 1.61M | 7.00M | 1.64M | -3.70M | 18.1M | 9.81M | 2.14M | 1.50M |
| Share buybacks | 5.98M | 9.18M | 4.31M | 9.01M | 1.01M | 92.0K | ||||
| Change in cash | -558.0K | 3.35M | -1.41M | 1.72M | -3.80M | -8.26M | 16.9M | 968.0K | -589.0K | -1.20M |
Cap table
Built by 6ix from Optomed Oyj Class A’s releases · as of Dec 10, 2025
- Common shares
- 21,473,869
- Fully diluted
- 21,473,869
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 21,473,869 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 21,473,869 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Catherine Calarco | Member of the Board of Directors · Since at least May 8, 2026 |
| Juho Himberg | CEO · Since at least Sep 21, 2026 |
| Kristiina Leppänen | Member of the Board of Directors · Since at least May 8, 2026 |
| Laura Piila | Vice President, Devices · Since at least Nov 5, 2026 |
| Leana Wen | Member of the Board of Directors · Since at least May 8, 2026 |
| Markku Myllylä | Vice President, Software · Since at least Jan 21, 2026 |
| Petri Salonen | Chairman of the Board of Directors · Since at least Sep 25, 2026 |
| Reijo Tauriainen | Member of the Board of Directors · Since at least May 8, 2026 |
| Sakari Knuutti | Chief Financial Officer · Since at least Aug 14, 2026 |
| Sameer Badlani | Member of the Board of Directors · Since at least May 8, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Seppo Mäkinen | Member of the Board of Directors · Since at least May 8, 2026 |
| Ty Lee | Member of the Board of Directors · Since at least May 8, 2026 |
Log in to ask 6ix AI your own questions about Optomed Oyj.